Join Now

Category Archives: BioUtah News

US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix

By Natalie Themm | Published October 12, 2023

US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix

| Tagged | Comments Off on US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

By admin | Published October 5, 2023

Funding to Support Research and Expanded Access of Investigational Drug in ALS SALT LAKE CITY, Oct. 05, 2023 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc. in collaboration with Columbia University and Synapticure, has been awarded a four-year grant totaling $45.1 million from the National Institute of Neurological […]

| Comments Off on National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Owlet Commits Critical Support To Parents and Researchers On A Mission To End SIDS

By admin | Published October 5, 2023

LEHI, Utah–(BUSINESS WIRE)– Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), a pioneer of smart baby monitoring, is on a mission to raise critical funds for research that could bring an end to sudden infant death syndrome (SIDS). Owlet is partnering in this effort with Dr. Carmel Harrington, Honorary Research Fellow at Sydney Children’s Hospital […]

| Comments Off on Owlet Commits Critical Support To Parents and Researchers On A Mission To End SIDS

New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

By Natalie Themm | Published September 28, 2023

New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

| Tagged | Comments Off on New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

Medical Technology Company Focused on Vessel Preparation, Dilation, And Treatment Delivery Secures Series B Funding

By Natalie Themm | Published September 28, 2023

Medical Technology Company Focused on Vessel Preparation, Dilation, And Treatment Delivery Secures Series B Funding

| Tagged | Comments Off on Medical Technology Company Focused on Vessel Preparation, Dilation, And Treatment Delivery Secures Series B Funding

Biomerics Announces Completion of 100,000 sq. ft. Expansion of Brooklyn Park, MN, Facility

By Natalie Themm | Published September 28, 2023

Biomerics Announces Completion of 100,000 sq. ft. Expansion of Brooklyn Park, MN, Facility

| Tagged | Comments Off on Biomerics Announces Completion of 100,000 sq. ft. Expansion of Brooklyn Park, MN, Facility

Audio-based Detection of Anxiety and Depression via Vocal Biomarkers

By Natalie Themm | Published September 28, 2023

Audio-based Detection of Anxiety and Depression via Vocal Biomarkers

| Tagged | Comments Off on Audio-based Detection of Anxiety and Depression via Vocal Biomarkers

bioMérieux submits Dual 510(k) and CLIA-waiver application to FDA for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel

By Natalie Themm | Published September 28, 2023

Marcy-l’Étoile (France), September 22nd, 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, has submitted the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel to U.S. Food and Drug Administration (FDA) for a dual 510(k) clearance and CLIA1-waiver. This panel is already CE-marked (IVDD2).

| Tagged | Comments Off on bioMérieux submits Dual 510(k) and CLIA-waiver application to FDA for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel

Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

By admin | Published September 21, 2023

Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only test SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN), a global leader in […]

| Comments Off on Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

Myriad Genetics Issues 2022 Environmental, Social and Governance Report

By admin | Published September 21, 2023

SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its second annual Environmental, Social and Governance report, highlighting key efforts that reflect its commitment to conduct operations as a responsible, equitable and sustainable partner in the healthcare industry. “At Myriad, […]

| Comments Off on Myriad Genetics Issues 2022 Environmental, Social and Governance Report

Rep. Moore’s Health Staff Visits Utah Life Sciences Companies

By Natalie Themm | Published September 21, 2023

Rep. Moore’s Health Staff Tours Visits Utah Life Sciences Companies

| Comments Off on Rep. Moore’s Health Staff Visits Utah Life Sciences Companies

Partnership and innovation help SSM Health secure lower-cost, reliable supply of generic drugs

By Natalie Themm | Published September 21, 2023

Civica Rx, a health care utility co-founded by SSM Health, supplies critical medications that patients need.

| Tagged | Comments Off on Partnership and innovation help SSM Health secure lower-cost, reliable supply of generic drugs

A Special Thanks To Our Legacy and Platinum Elite Members